US prostate cancer news: screening guidelines get major update


The latest of my "30 articles in one month" series to raise money for prostate cancer research covers news of updated guidelines for prostate cancer screening in the US.

  American Cancer Society announces new prostate cancer screening guidelines

 [Note: I pledged to produce 30 articles in one month, even though I'm currently undergoing prostate cancer treatment, to achieve a fundraising goal. Please consider donating here and sharing a link to this blog (CobbsBlog.com) on social media.]

As a public health issue, prostate cancer (PCa), has grown rapidly this century and is now comparable in scale to breast cancer (BCa). By some key numerical measures PCa has now overtaken BCa, for example in terms of UK deaths, recent UK diagnoses, and projected US new cases. The American Cancer Society has projected 333,830 new prostate cancer cases in 2026. Screening men for early signs of prostate cancer can reduce the death toll and the impact of treatment.

Good news! Major improvements in US prostate cancer screening guidelines

I'm genuinely excited that the American Cancer Society chose this month, November, 2026 to announce major changes to its prostate cancer screening guidelines, intended to improve detection and treatment of a disease that is projected to result in 33,000 deaths in the US this year. 

There is an excellent article about the changes in The Conversation, which interviewed Dr. Andrew Wolf, a physician at the University of Virginia who was one of the lead authors of the new guidelines. He walks readers through the changes and why they were made. 

A fundamental change is a call for proactive screening for prostate cancer. Instead of just recommending that people talk with their healthcare provider to decide whether or not screening is right for them, the new recommendation is urging doctors to act, based on factors like age and a person’s risk of developing prostate cancer. For example, for people at average risk of developing prostate cancer:

we recommend they be screened with the prostate-specific antigen, or PSA, blood test every two years from age 50 through 69.

(If that level of screening were to be adopted universally, in American and beyond, many prostate cancer deaths would be avoided and millions of men would stand a better chance of avoiding the suffering caused by late intervention and treatment.)

More specifically, the new recommendation for people at higher risk, including Black men and men with a strong family history of prostate cancer, is that they should be screened annually from age 45 to 69. 

A strong family history is defined as having a family member who was diagnosed with prostate cancer before age 65, or multiple family members diagnosed at any age. 

Furthermore, "people with a single family member diagnosed at age 65 or older should be screened every two years from age 45 years to age 69 years."

The article goes on to explain why the changes were made and what the current views are on the risks of prostate cancer. The full 36-page guidelines document is available here. I strongly recommend reading the account in The Conversation, 

In my article about PSA testing I mentioned that I would address arguments about prostate cancer screening. I'm not going to do that here. However, I do need to point out that there are considerable differences between countries on this topic, due in part to the way those countries are structured. 

For example, if you have a national universal healthcare system (e.g. England), then screening guidelines for health-related issues can become requirements that must be funded. However, if you don't have a national universal healthcare system (e.g. USA), then medical guidelines are more aspirational, as in "this is what we hope will happen" versus "here's what has to happen by law."

I explained the way these differences manifest themselves in the the implementation of cancer screening guidelines in this article.

P.S. I love the fact that the image at the top of the article, a screenshot of the American Cancer Society page announcing the changes to prostate cancer screening guidelines, features happy women. It reminds me of the conversation I overheard on day at the cancer treatment centre where I got my radiotherapy. Two women were talking, the receptionist and a woman who had brough her husband in for treatment, and they were strongly agreeing with each other that "every man should be screened, just like everyone with breasts is screened."


Prostate cancer Q&A: How will I know if the radiotherapy worked?


Some of the articles in the 30-article series that I am publishing to raise money for prostate cancer research are answers to readers' questions. Today's question is about assessing the results of radiotherapy treatment.

Photo of radiotherapy machine in use for prostate cancer treatment Memorial Sloan Kettering Cancer Center
  Radiotherapy machine being used for prostate cancer treatment

[Note: I pledged to produce these articles while undergoing prostate cancer treatment, to raise money for the Movember charity which funds a lot of prostate cancer research and support. Please consider donating here and sharing a link to this blog (CobbsBlog.com) on social media.]

So, here is the exact wording of the reader's question: 

"How will they know how well the IMRT worked?" 

IMRT is a form of radiotherapy that the reader is considering and he wants to know how doctors determine the extent to which it succeeds in killing cancer cells.

For readers who don't recognize IMRT, it stands for Intensity-Modulated Radiation Therapy (IMRT), a type of external-beam radiotherapy used to treat localised prostate cancer, i.e. cancer that is in or very close to the prostate gland. 

As it happens, this is the type of radiotherapy that I had. (It was on a machine a bit like the one in picture at the top of the article, but there were no modesty blankets involved, staff just had you lie flat on the deck and drop your trousers and underwear.) 

My IMRT was delivered using a technique called Volumetric Modulated Arc Therapy (VMAT). Rather than delivering radiation from a series of fixed positions, VMAT delivers a continuously modulated beam while the machine rotates around the patient.

The question of how to determine if this treatment has been effective in a logical one, but the answer is somewhat frustrating: it's hard to know for sure, at least not straight away. In fact, it can take years, which is not exactly encouraging, but there are reasons for this.

Unlike surgery, where the prostate is removed and examined, radiotherapy leaves the prostate in place and there is no simple test that tells you if all the cancer cells have been destroyed.

What doctors can do is monitor PSA levels using blood tests (described here in a previous article). Successful radiotherapy should cause PSA levels to fall considerably, although they won't necessarily reach zero because healthy prostate cells are still producing some PSA.

This decline can take quite a while. It may be 18 months to three years before PSA reaches its lowest level, known as the nadir. And even after that a small temporary increase in PSA may occur, but that doesn't necessarily mean the cancer is returning. (There's a recognised phenomenon called PSA bounce, where the level rises briefly before falling again.)

For patients like me, who received radiotherapy combined with androgen deprivation therapy (ADT), there's an additional complication. ADT suppresses testosterone, which also reduces PSA production. So a low PSA reading while taking ADT is encouraging, but it doesn't tell us how much of the improvement is due to radiotherapy and how much is due to hormone suppression. 

In March of this year, before any treatment, my PSA was 7.50. After 50 days of ADT it was 0.47. In July I had the IMRT. About 75 days after the IMRT was completed my PSA was 0.45. The ADT doesn't end until the end of March and the drug won't clear my system right away. Realistically, it could be MAY until I get a PSA reading that is not influenced by testosterone suppression.

When ADT ends and testosterone recovers, PSA may rise somewhat, but that does not mean the cancer has returned. As I have said before, it is the trend of PSA numbers that matters. One widely accepted definition of recurrence after radiotherapy is a PSA increase of 2 above its lowest recorded level, but a  persistent upward trend may prompt investigation even before that threshold is reached.

(In the UK, the NHS recommends PSA checks at least every six months for the first two years following radical treatment, and annually thereafter. Routine scans or biopsies are generally unnecessary unless PSA results or symptoms suggest a problem.)

So the short answer is that the success of IMRT is judged over time, through regular PSA testing. A sustained low PSA is very good news and the longer it stays low, the more confident one can be that the treatment has done its job.

Types of radiotherapy

To put IMRT in context, here is a table based on info from Prostate Cancer UK, which has an excellent page on radiotherapy that is worth reading.

Technique

How it works

Current role

3D Conformal Radiotherapy (3D-CRT)

Uses CT-based planning to shape radiation beams to the prostate.

Older technique, largely superseded by IMRT for prostate cancer.

Intensity-Modulated Radiotherapy (IMRT)

Adjusts the intensity of radiation across individual beams, reducing exposure to surrounding tissues.

Standard UK treatment.

Volumetric Modulated Arc Therapy (VMAT)

A form of IMRT in which the machine rotates around the patient, continuously adjusting the beam.

Widely used in NHS radiotherapy centres.

Stereotactic Body Radiotherapy (SBRT/SABR)

Delivers very precise, higher doses of radiation in fewer sessions, often five.

Increasingly used for selected prostate cancers. 

Proton Beam Therapy (PBT)

Uses protons rather than X-ray photons, potentially reducing radiation beyond the target.

Not routine NHS treatment for localised prostate cancer; clinical benefit over modern IMRT remains uncertain.


One of the leading makers of radiotherapy equipment is Elekta. The company's website has some useful educational materials including more extensive list of different types of radiotherapy.



Prostate cancer: where to get help, advice, and support


This article is one of 30 that I am publishing to raise money for prostate cancer research. It lists major sources of help and support across multiple countries..

Image of eight men shown as icons, with one a different colour to show 1 in 8 men get prostate cancer
Prostate cancer prevalence is 1 in 8, even higher among black men
(from Prostate Cancer UK) 

[Note: I pledged to produce these articles, even though I'm currently undergoing prostate cancer treatment, for a fundraising pledge to which you can donate here. Please consider doing so and sharing a link to this blog (CobbsBlog.com) on social media.]

Getting a prostate cancer diagnosis can leave you with a lot of questions. Even after treatment has started, questions will likely keep coming up. Some concern the disease itself, others the side effects of treatment, and still others the impact on relationships, work, and everyday life (whether you are working or retired or retired but caring for a loved one). 

Fortunately, there are organisations that can help. Some have specialist nurses available to answer questions, while others can put you in touch with people who have already been through similar experiences. Most offer their services free of charge, and many also provide support for partners and families. 

For me, online support forums have been helpful. I starting hanging out at Prostate Cancer UK even before I had the results of my first MRI. Everyone was understanding and supportive. I suggest finding a forum sooner rather than later. Problems involving sexual function, fatigue, sleep, mood, continence, or relationships are legitimate reasons to engage with fellow patients, in addition to contacting a support organisation's clinical team about treatment or rehabilitation options.

I also found the nurse specialists at my cancer treatment centre to be very helpful. They pointed me to a local support group and I have found it helpful to attend some of their meetings.

United Kingdom

Prostate Cancer UK: Support services. Specialist nurses, confidential advice, online communities, and one-to-one peer support. Free helpline: 0800 074 8383. 

Tackle Prostate Cancer: tackleprostate.org. The National Federation of Prostate Cancer Support Groups. Particularly useful for finding local groups, meeting fellow patients and getting help with treatment decisions. 

Macmillan Cancer Support: Website and support line. Advice on cancer treatment, emotional wellbeing, finances, benefits and practical problems. Free helpline: 0808 808 00 00. 

Prostate Cancer Research: The Infopool. Patient-friendly information on diagnosis, treatment choices, clinical trials, managing side effects and life after treatment. Includes personal experiences from patients and partners. 

United States

ZERO Prostate Cancer: Help and support. National prostate cancer support organisation offering patient navigation, local and online support groups, one-to-one mentoring, and financial assistance guidance. ZERO360 helpline: 1-844-937-6360. 

Prostate Cancer Foundation (PCF): Support includes extensive patient education covering diagnosis, treatments, side effects, sexual health, clinical trials and survivorship. Free patient guides and webinars. 

Prostate Cancer Research Institute (PCRI): Evidence-based information, videos, educational conferences and a free patient helpline. Particularly useful when understanding treatment options and navigating complex decisions. 

CancerCare: Prostate cancer support. Free professional counselling, support groups, practical advice and financial assistance resources for patients and their families. 

Canada

Prostate Cancer Foundation Canada: National network offering prostate cancer support groups, peer support, information and education. Patient support: 604-834-7757. Toll-free general contact: 1-877-840-9173. 

Canadian Cancer Society: Cancer Information Helpline. Confidential information about cancer treatment, side effects, emotional wellbeing, clinical trials and community services. Available in English and French, with interpretation for other languages. Toll-free: 1-888-939-3333. 

CancerConnection.ca: Online support community. A free, moderated online community operated by the Canadian Cancer Society, connecting patients, survivors, partners and caregivers to share experiences and advice. 

Australia

Prostate Cancer Foundation of Australia (PCFA): National prostate cancer support services including specialist nurses, peer mentoring through MatesCONNECT, online communities and local support groups. Free helpline: 1800 22 00 99. 

PCFA Prostate Cancer Counselling Service: Counselling service. Specialised counselling for the emotional and psychological effects of prostate cancer, including sexual concerns, relationships, anxiety and depression. Offers up to five consultations without charge. Access via 1800 22 00 99. 

Cancer Council Australia: National cancer information, emotional and practical support, and referrals to local services. Telephone: 13 11 20. 

New Zealand

Prostate Cancer Foundation of New Zealand (PCFNZ): Support services. Specialist information, counselling, online forums, local support groups, exercise programmes and assistance for patients and their families. Information service: 0800 66 0800. 

Cancer Society of New Zealand: Cancer information nurses, counselling and practical support, including transport to treatment and assistance for families and carers. Free helpline: 0800 CANCER (0800 226 237). 

PCFNZ Local Support Groups: Nationwide directory connecting patients and families with local groups and experienced volunteers. Includes groups specifically for partners and informal one-to-one support. 

Cancer Screening: Prostate and breast cancer compared, US and UK


For the tenth article in the 30-article series I'm publishing to raise money for prostate cancer research I look at the differences between prostate and breast cancer screening in the US and UK.

 Caption: PSA blood test for prostate cancer screening
 & mammogram for breast cancer screening

[Note: I pledged to produce these articles, even though I'm currently undergoing prostate cancer treatment, for a fundraising pledge to which you can donate here. Please consider doing so and sharing a link to this blog (CobbsBlog.com) on social media.]

As someone who has lived for decades in both the UK and America I have noticed significant differences in how the two countries check for breast and prostate cancers. The US relies heavily on automatic, aggressive screening starting at younger ages. The UK takes a more conservative approach based on population health data, waiting longer to start routine tests and avoiding them entirely if the risks outweigh the benefits. 
The primary difference lies in how their medical systems work: the US often urges screening of individual patients earlier, but lacks a system to enforce this; the UK uses structured national programmes that only invite specific age groups, but has established mechanisms to make sure the screening happens. 
I thought it would be interesting to look at how prostate and breast cancer screening compare these days, given that the incidence of prostate cancer (PCa), has increased significantly this century and is now comparable in scale to breast cancer (BCa). By some key numerical measures PCa has now overtaken BCa, for example in terms of UK deaths, recent UK diagnoses, and projected US new cases.

Breast cancer screening

Both countries use mammograms (breast X-rays) to look for early signs of cancer, but who gets invited and how often varies greatly:

Screening Factors United States (US)United Kingdom (UK)
Starting Age Age 40 (Recommended by the US Preventive Services Task Force)Age 50 to 53 (Automatically invited by the NHS Breast Screening Programme)
How OftenEvery 1 to 2 years (Depending on the specific medical guideline)Every 3 years
Stopping AgeOften up to age 74, or as long as life expectancy is 10+ yearsAutomatically stops at age 71 (Though you can still request free tests)
US guidelines focus on catching cancer as early as possible in individuals. UK experts believe that routine screening for women under 50 causes more harm than good, such as unnecessary anxiety and extra testing for harmless lumps.

Prostate cancer screening

Neither the UK nor the US has a standard, automatic national screening programme for the general public. Both use the PSA blood test (Prostate-Specific Antigen), but their strategies differ significantly:
  • United States (Shared Decision Making): The US Preventive Services Task Force recommends that men aged 55 to 69 talk to their doctors to make a personal choice about screening. Doctors routinely offer this conversation during yearly checkups.
  • United Kingdom (Informed Choice / Targeted): The UK National Screening Committee explicitly advises against general population screening. Under the NHS Prostate Cancer Risk Management Programme, GPs do not proactively bring up the test. However, any man over 50 can request a free PSA test if they ask for it. The NHS only proactively invites men aged 45 to 61 if they have a known high-risk genetic mutation like BRCA2.
A major challenge for prostate cancer screening is that the PSA blood test is not a reliable as a direct indicator of cancer. It can show high levels due to a naturally enlarged prostate or an infection. The UK strictly limits its use because diagnosing slow-growing prostate cancers can lead to invasive treatments (like surgery) that cause side effects like impotence or incontinence, even if the cancer was never going to threaten the man's life. 

How is screening policy implemented?

A major reason for the differences in approach to cancer screening in different countires is the different ways in which those countries are structured. For example, if you have a national universal healthcare system (e.g. England), then screening guidelines for health-related issues can become requirements that must be funded. However, if you don't have a national universal healthcare system (e.g. USA), then medical guidelines are more aspirational, as in "this is what we hope will happen" versus "here's what has to happen by law." Here's a brief comparison:
  • UK: Screening policy is coordinated nationally by the UK National Screening Committee (UK NSC), which evaluates evidence on population benefit versus harm. Clinical pathways and referral standards are subsequently shaped by the National Institute for Health and Care Excellence (NICE) and delivered uniformly through the National Health Service (NHS).
  • US: There is no single, centralized national screening program. Instead, guidelines are issued by a mosaic of federal task forces (such as the US Preventive Services Task Force, or USPSTF), government research bodies (like the National Institutes of Health / National Cancer Institute, NIH/NCI), and professional organizations (such as the American Cancer Society, ACS, and specialty medical colleges). Screening frequently happens opportunistically during routine clinical encounters, heavily mediated by health insurance coverage.
When it comes to screening for PCa, what the UK and USA have in common is strong debate about the correct approach. Recent decisions in the UK appear to restrict PCa screening, and there has been strong pushback. Meanwhile in America, the American Cancer Society is expected to release revised PCa screening guidelines this month.


Prostate cancer treatment: side effects and impacts


In this, the ninth article in my 30-article series to raise money for prostate cancer research during November, 2026, I look at things you need to think about if doctors recommend "radical treatment" for your prostate cancer.

Photo of a man dealing with distress. Thanks to Romario Roges for sharing this photo on Unsplash

[Note: I pledged to produce these articles, even though I'm currently undergoing prostate cancer treatment, for a fundraising pledge to which you can donate here. Please consider doing so and sharing a link to this blog (CobbsBlog.com) on social media.]

As I discussed in a previous article, "radical treatment" for prostate cancer means taking drastic action to get rid of the cancer cells. There are two main courses of action and both come with serious side effects. On the one hand there is surgery to remove the prostate. 

On the other hand there is RT+ADT, which involves leaving the prostate in place and killing the cancer cells by targeting them with X-rays (radiotherapy or RT). The +ADT comes from the use of drugs to deprive prostate cancer cells of the testosterone on which they thrive. This drug component of prostate cancer treatment is called hormone ablation.

The most common form of hormone ablation is called Androgen Deprivation Therapy or ADT. In the words of my urologist, "ADT will totally crush your testosterone." He was not wrong, after 50 days on ADT tablets (Relugolix) my testosterone was 0.69 nmol/L or 19.90 ng/dL in American terms. That is well below the level known as chemical castration (1.7 nmol/L or 50 ng/dL).

As far as I can tell, using ADT with radiotherapy is standard practice in the UK although the length of time you are on the ADT can vary (from six months to 18 months or sometimes longer — I'm 7.5 months into a 12 month course).

Surgery side effects

The main side effects of surgery involve urinary control and sexual function. Many men experience urinary incontinence following surgery and this may mean wearing a catheter for a while, although the incontinence often diminishes over time.

Erectile dysfunction is also common because the nerves responsible for erections run alongside the prostate and can be damaged during its removal. 

If the cancer is caught soon enough and is confined to certain parts of the prostate, there is a form of prostate surgery called nerve-sparing that can try to avoid nerve damage. Regrettably my cancer was not caught in time for the nerve-sparing option to be available; however, even nerve-sparing surgery cannot guarantee that erectile function will recover. 

Furthermore, removing the prostate and seminal vesicles means that ejaculation of semen becomes permanently impossible. Men can still experience orgasms, but these are dry orgasms, which may feel different or less satisfying. 

Surgery also eliminates the ability to father children through sexual intercourse. For younger men this may be a major concern, but sperm banking (cryopreservation) is an option: you provide a semen sample at a specialized fertility clinic or hospital before your surgery takes place. The sample is frozen in liquid nitrogen and can be stored for years

All in all, prostate surgery comes with some pretty drastic effects that need to be processed. For some men these consequences may be manageable; for others they may represent a profound change in their sexual identity, relationships and sense of wellbeing. Age, culture, and personal circumstances will all play a part in the processing.

RT+ADT side effects

The side effects of RTHA come from two directions. Radiotherapy can irritate or damage nearby tissues, causing urinary urgency, frequent urination, bowel disturbances, rectal bleeding and, sometimes, long-term erectile dysfunction. 

Hormone therapy (ADT) adds a second and potentially more widespread set of problems. Suppressing testosterone can dramatically reduce sexual desire and erectile function, while also producing fatigue, hot flushes, disturbed sleep, loss of muscle mass, weight gain, mood changes and difficulties with concentration or motivation. 

Longer-term treatment with ADT can weaken bones, alter cholesterol levels, increase insulin resistance and raise the risk of diabetes and cardiovascular disease. Some effects improve after hormone treatment stops, but recovery can take months or even years, and some changes may persist. 

As someone who chose RT+ADT over surgery, I will be documenting how things go at the end of my hormone treatment. I take my last Relugolix pill on the morning of March 31, 2026 — not that I'm counting the days). 

The immediate post-ADT phase comes with its own stress factors because the extent to which the radiotherapy eradicated your cancer cells cannot be determined until you stop suppressing your testosterone.

The future of prostate cancer treatment 

The current irony of prostate cancer treatment is that something intended to prolong your life can simultaneously make that life considerably more difficult to enjoy. I firmly believe that this will change over time. Later this month I will be talking about promising new directions in prostate cancer treatment, like the one I described here.

In the meantime, donating to prostate cancer research programs makes sense to me, as does lobbying your government, spreading the word, and taking part in research projects. I hope to highlight some of those in a future article as well as describe one in which I participated.